Non-inferiority of Pharmacological Prevention Alone Versus Pancreatic Stents to Prevent Post-ERCP Pancreatitis
Non-inferiority Trial Comparing Pharmacological Prevention Alone Versus Pancreatic Stents Plus Pharmacological Prevention to Prevent Post-ERCP Pancreatitis
1 other identifier
interventional
400
1 country
1
Brief Summary
Pancreatitis is the most important complication of ERCP. The severity of this condition varies from mild to severe and can lead to prolonged hospitalization, surgical interventions, and even death. Several patient-related and procedure related factors have been identified that are associated with a higher risk of post-ERCP pancreatitis. So far, several methods have been proposed to avoid pancreatitis in patients at higher risk of this complication. Several studies have shown that different drug therapies (indomethacin suppository, a sublingual nitrate tablet and the administration of intravenous Ringer's solution) each may reduce the incidence of post-ERCP pancreatitis. All these drug therapies are safe, cheap and easy to administer. Several other studies have shown that pancreatic duct stenting (placement of a plastic tube in the pancreatic duct) is an effective intervention in preventing and reducing the severity of post-ERCP pancreatitis, especially in high-risk groups. However, there are still a few drawbacks to consider with pancreatic duct stenting: there are some difficulties with insertion of a PD stent, it is associated with a need for radiological follow-up and/or repeat endoscopy for removal, higher cost and a small but important risk of complications (e.g. stent migration). Most of the clinical trials of pancreatic duct stenting were performed, before the results of trials of drug therapies were available. Moreover, no RCT (to the investigators knowledge) has compared the efficacy of pancreatic duct stenting in patients who already received a combination of drug therapies to prevent post-ERCP pancreatitis in high-risk patients. The purpose of this study is to determine the noninferiority of a combination of drug therapies in relation to pancreatic duct stenting to prevent post-ERCP pancreatitis in high-risk patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2015
CompletedFirst Submitted
Initial submission to the registry
February 2, 2015
CompletedFirst Posted
Study publicly available on registry
February 23, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2017
CompletedNovember 6, 2015
November 1, 2015
1.9 years
February 2, 2015
November 5, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Post-ERCP pancreatitis
Pancreatitis is defined as new or worsened abdominal pain and tenderness with amylase levels at least three times above the upper limit of normal at 24 hours after the procedure, requiring hospital admission or a prolongation of planned admission.
24 hours after ERCP
Secondary Outcomes (1)
Severity of acute pancreatitis according to revised Atlanta classification (Banks et al. GUT 2013)
One week after ERCP
Study Arms (2)
Pharmacological Prevention
PLACEBO COMPARATORCombination of rectal indomethacin, sublingual isosorbide dinitrate and intravenous hydration with Ringer's lactate serum without pancreatic stenting
Pancreatic Stent
ACTIVE COMPARATORPancreatic Stent PLUS Pharmacological Prevention
Interventions
A 5-Fr, 4-cm-long stent (Endoflex) with a single duodenal pigtail is used for pancreatic duct stenting
Indomethacin 100 mg suppository ten minutes before ERCP
Sublingual Isosorbide dinitrate 5 mg before ERCP
IV Ringer's lactate serum with a dose of 6 cc/kg/h during the procedure and 20 cc/kg after ERCP as a bolus dose and 3 cc/kg/h for the next 8 hours.
Eligibility Criteria
You may qualify if:
- Patients at high risk of post-ERCP Pancreatitis undergoing ERCP are eligible to enter the study. At least one major or two minor criteria must be present for the patient to be considered at high risk for PEP:
- Major
- Sphincter of Oddi dysfunction.
- History of previous PEP.
- Pancreatic injection.
- Precut sphincterotomy.
- Balloon sphincter dilation without sphincterotomy.
- Pancreatic guidewire passages \> 1.
- Minor
- Female patients aged\<60 years.
- Nondilated common bile duct (CBD).
- Normal serum bilirubin (\<2mg/dl).
- Failure to clear bile duct stones.
- Failed cannulation.
- Difficult cannulation (Time to CBD cannulation more than 10 min or more than five attempts at cannulation).
You may not qualify if:
- Age younger than 15 years.
- History of sphincterotomy.
- Surgically altered anatomy (Billroth II gastrectomy or Roux-en-Y anastomosis).
- Uncontrolled coagulopathy.
- Tumor of ampulla of Vater.
- Those undergoing routine biliary-stent exchange.
- Acute pancreatitis at the time of ERCP.
- Chronic pancreatitis.
- Regular NSAID use during preceding week.
- Unable to tolerate indomethacin (Creatinine level \>1.4 mg/dL or active peptic ulcer disease).
- Unable to tolerate nitrates (closed-angle glaucoma).
- Unable to tolerate aggressive hydration (cardiac insufficiency: NYHA FC II or higher, renal insufficiency, electrolyte disturbances, clinical signs of fluid overload including peripheral or pulmonary edema, liver dysfunction with varix\>F1, or respiratory insufficiency).
- Patients requiring pancreatic duct drainage: to bridge dominant strictures, bypass obstructing pancreatic duct stones, drain pseudocysts, seal duct disruptions, pancreatic head cancer with main PD obstruction, IPMN or Pancreas divisum.
- Known main pancreatic duct stricture toward the head of pancreas.
- Pregnancy or breastfeeding.
- +1 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Shariati hospital
Tehran, Tehran Province, 1411713135, Iran
Related Publications (1)
Sotoudehmanesh R, Ali-Asgari A, Khatibian M, Mohamadnejad M, Merat S, Sadeghi A, Keshtkar A, Bagheri M, Delavari A, Amani M, Vahedi H, Nasseri-Moghaddam S, Sima A, Eloubeidi MA, Malekzadeh R. Pharmacological prophylaxis versus pancreatic duct stenting plus pharmacological prophylaxis for prevention of post-ERCP pancreatitis in high risk patients: a randomized trial. Endoscopy. 2019 Oct;51(10):915-921. doi: 10.1055/a-0977-3119. Epub 2019 Aug 27.
PMID: 31454851DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 2, 2015
First Posted
February 23, 2015
Study Start
February 1, 2015
Primary Completion
January 1, 2017
Last Updated
November 6, 2015
Record last verified: 2015-11